ANTINEOPLASTIC combined chemotherapy protocolsObjective: To compare the short-term and long-term efficacy of FLOT and FOLFOX in the treatment of advanced gastric cancer (GC), as well as their effects on serum tumor markers and NRP-2. Methods: 82 patients with...
FLOT和SOX是研究常用方案,占90%。其他方案包括FOLFOX、CAPOX、DCF方案,均为临床常用方案。所有患者术前平均接受4个周期的NAC治疗。PSM前后,三药治疗队列中性粒细胞减少和贫血发生率较高,而血小板减少在双药队列中更为常见。3/4级血液学毒性的发生率差异无统计...
Conclusion: FLOT and FOLFOX are both effective chemotherapy regimens for mid to late stage GC, with consistent safety. However, the former has advantages in improving objective efficacy, reducing serum tumor markers and NRP-2 levels, and prolonging survival. 展开 ...
Rates of ypN0 were 50.5% in FLOT arm and 43.7% in XELOX/FOLFOX arm (p=0.36). pCR was achieved in 8.2% and 6.3% in FLOT and XELOX/FOLFOX arms, respectively (p=0.59). Median PFS was 20.3 mth in FLOT arm in comparison to 15.7 mth in FOLFOX/XELOX arm (p=0.012). Median OS was ...
There is no preference for postoperative chemotherapy with the two common treatment regimens, FLOT and FOLFOX, in these patients. The aim of this study was to compare FOLFOX and FLOT regimens in perioperative chemotherapy in resectable GC based on pathological response and complications. Methods: ...